What is the long-term trend for Monte Rosa Therapeutics, Inc.'s operating lease liabilities?

Over 2 years (2023 to 2025), Monte Rosa Therapeutics, Inc.'s operating lease liabilities has grown at a -67.7% compound annual growth rate (CAGR), from $10.37M to -$1.08M.

Monte Rosa Therapeutics, Inc. GLUE Operating lease liabilities

Operating lease liabilities at other companies

Nurix Therapeutics, Inc.NRIX

——

ImmunomeIMNM

——

TG TherapeuticsTGTX

——

Protagonist TherapeuticsPTGX

——

Apogee Therapeutics, Inc.APGE

——

Alumis Inc.ALMS

——

Segments

By geography

See full

Klybeckstrasse Lease$1M—

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.76B+361%

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s operating lease liabilities?: Monte Rosa Therapeutics, Inc. (GLUE) reported operating lease liabilities of -$434K in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s operating lease liabilities changed year-over-year?: Monte Rosa Therapeutics, Inc.'s operating lease liabilities decreased by 53.4% year-over-year, from -$283K to -$434K.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s operating lease liabilities?: Over 2 years (2023 to 2025), Monte Rosa Therapeutics, Inc.'s operating lease liabilities has grown at a -67.7% compound annual growth rate (CAGR), from $10.37M to -$1.08M.